Literature DB >> 1710290

Suppression of retroviral MA deletions by the amino-terminal membrane-binding domain of p60src.

J W Wills1, R C Craven, R A Weldon, T D Nelle, C R Erdie.   

Abstract

The molecular mechanism by which retroviral Gag proteins are directed to the plasma membrane for the formation of particles (budding) is unknown, but it is widely believed that the MA domain, located at the amino terminus, plays a critical role. Consistent with this idea, we found that small deletions in this segment of the Rous sarcoma virus Gag protein completely blocked particle formation. The mutant proteins appear to have suffered only localized structural damage since they could be rescued (i.e., packaged into particles) when coexpressed with Gag proteins that are competent for particle formation. To our surprise, the effects of the MA deletions could be completely suppressed by fusing as few as seven residues of the myristylated amino terminus of the oncoprotein p60src to the beginning of the mutant Gag proteins. Particles produced by the chimeras were of the same density as the wild type. Two myristylated peptides having sequences distinct from that of p60src were entirely unable to suppress MA deletions, indicating that myristate alone is not a sufficient membrane targeting signal. We hypothesize that the amino terminus of p60src suppresses the effects of MA deletions by diverting the Rous sarcoma virus Gag protein from its normal site of assembly to the Src receptor for particle formation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1710290      PMCID: PMC241411     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Activation of the cellular proto-oncogene product p21Ras by addition of a myristylation signal.

Authors:  J E Buss; P A Solski; J P Schaeffer; M J MacDonald; C J Der
Journal:  Science       Date:  1989-03-24       Impact factor: 47.728

Review 2.  Fatty acylation of proteins.

Authors:  A M Schultz; L E Henderson; S Oroszlan
Journal:  Annu Rev Cell Biol       Date:  1988

3.  Standardized and simplified nomenclature for proteins common to all retroviruses.

Authors:  J Leis; D Baltimore; J M Bishop; J Coffin; E Fleissner; S P Goff; S Oroszlan; H Robinson; A M Skalka; H M Temin
Journal:  J Virol       Date:  1988-05       Impact factor: 5.103

4.  The first seven amino acids encoded by the v-src oncogene act as a myristylation signal: lysine 7 is a critical determinant.

Authors:  J M Kaplan; G Mardon; J M Bishop; H E Varmus
Journal:  Mol Cell Biol       Date:  1988-06       Impact factor: 4.272

5.  The absence of myristic acid decreases membrane binding of p60src but does not affect tyrosine protein kinase activity.

Authors:  J E Buss; M P Kamps; K Gould; B M Sefton
Journal:  J Virol       Date:  1986-05       Impact factor: 5.103

6.  High affinity binding of an N-terminal myristoylated p60src peptide.

Authors:  C Goddard; S T Arnold; R L Felsted
Journal:  J Biol Chem       Date:  1989-09-15       Impact factor: 5.157

7.  The six amino-terminal amino acids of p60src are sufficient to cause myristylation of p21v-ras.

Authors:  J E Buss; C J Der; P A Solski
Journal:  Mol Cell Biol       Date:  1988-09       Impact factor: 4.272

8.  Nucleotide sequence of Rous sarcoma virus.

Authors:  D E Schwartz; R Tizard; W Gilbert
Journal:  Cell       Date:  1983-03       Impact factor: 41.582

9.  Amino acids encoded downstream of gag are not required by Rous sarcoma virus protease during gag-mediated assembly.

Authors:  R P Bennett; S Rhee; R C Craven; E Hunter; J W Wills
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

10.  An N-terminal peptide from p60src can direct myristylation and plasma membrane localization when fused to heterologous proteins.

Authors:  D Pellman; E A Garber; F R Cross; H Hanafusa
Journal:  Nature       Date:  1985 Mar 28-Apr 3       Impact factor: 49.962

View more
  87 in total

1.  Ubiquitin is part of the retrovirus budding machinery.

Authors:  A Patnaik; V Chau; J W Wills
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

2.  Insertion of capsid proteins from nonenveloped viruses into the retroviral budding pathway.

Authors:  N K Krishna; J W Wills
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

3.  In vivo interference of Rous sarcoma virus budding by cis expression of a WW domain.

Authors:  Akash Patnaik; John W Wills
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

4.  Nuclear entry and CRM1-dependent nuclear export of the Rous sarcoma virus Gag polyprotein.

Authors:  Lisa Z Scheifele; Rachel A Garbitt; Jonathan D Rhoads; Leslie J Parent
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-12       Impact factor: 11.205

5.  Membrane targeting properties of a herpesvirus tegument protein-retrovirus Gag chimera.

Authors:  J B Bowzard; R J Visalli; C B Wilson; J S Loomis; E M Callahan; R J Courtney; J W Wills
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

6.  Rapid localization of Gag/GagPol complexes to detergent-resistant membrane during the assembly of human immunodeficiency virus type 1.

Authors:  Rabih Halwani; Ahmad Khorchid; Shan Cen; Lawrence Kleiman
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

7.  Matrix protein of Akv murine leukemia virus: genetic mapping of regions essential for particle formation.

Authors:  E C Jørgensen; F S Pedersen; P Jørgensen
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

8.  Complementation studies with Rous sarcoma virus gag and gag-pol polyprotein mutants.

Authors:  S Oertle; N Bowles; P F Spahr
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

9.  Direct measurement of Gag-Gag interaction during retrovirus assembly with FRET and fluorescence correlation spectroscopy.

Authors:  Daniel R Larson; Yu May Ma; Volker M Vogt; Watt W Webb
Journal:  J Cell Biol       Date:  2003-09-29       Impact factor: 10.539

10.  p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease.

Authors:  M Huang; J M Orenstein; M A Martin; E O Freed
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.